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Abstract
Background/Aims: HBV has been classified into ten genotypes (A–J) and multiple subgenotypes, some of which strongly
influence disease outcome and their distribution also correlate with human migration. HBV infection is highly prevalent in
India and its diverse population provides an excellent opportunity to study the distinctiveness of HBV, its evolution and
disease biology in variegated ethnic groups. The North-East India, having international frontiers on three sides, is one of the
most ethnically and linguistically diverse region of the country. Given the paucity of information on molecular epidemiology
of HBV in this region, the study aimed to carry out an in-depth genetic characterization of HBV prevailing in North-East state
of Tripura.
Methods: From sera of chronically HBV infected patients biochemical/serological tests, HBV DNA quantification, PCR-
amplification, sequencing of PreS/S or full-length HBV genomes were done. HBV genotype/subgenotype determination and
sequence variability were assessed by MEGA5-software. The evolutionary divergence times of different HBV subgenotypes
were estimated by DNAMLK/PHYLIP program while jpHMM method was used to detect any recombination event in HBV
genomes.
Results: HBV genotypes D (89.5%), C (6.6%) and A (3.9%) were detected among chronic carriers. While all HBV/A and HBV/C
isolates belonged to subgenotype-A1 and C1 respectively, five subgenotypes of HBV/D (D1–D5) were identified including
the first detection of rare D4. These non-recombinant Indian D4 (IndD4) formed a distinct phylogenetic clade, had 2.7%
nucleotide divergence and recent evolutionary radiation than other global D4. Ten unique amino acids and 9 novel
nucleotide substitutions were identified as IndD4 signatures. All IndD4 carried T120 and R129 in ORF-S that may cause
immune/vaccine/diagnostic escape and N128 in ORF-P, implicated as compensatory Lamivudine resistance mutation.
Conclusions: IndD4 has potential to undermine vaccination programs or anti-viral therapy and its introduction to North-
East India is believed to be linked with the settlement of ancient Tibeto-Burman migrants from East-Asia.
Citation: Banerjee P, Mondal RK, Nandi M, Ghosh S, Khatun M, et al. (2014) A Rare HBV Subgenotype D4 with Unique Genomic Signatures Identified in North-
Eastern India –An Emerging Clinical Challenge? PLoS ONE 9(10): e109425. doi:10.1371/journal.pone.0109425
Editor: Ranjit Ray, Saint Louis University, United States of America
Received July 23, 2014; Accepted August 31, 2014; Published October 8, 2014
Copyright:  2014 Banerjee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files. The sequences of Indian HBV subgenotype D4 reported here are submitted to GenBank (accession numbers: KF192830 -KF192841).
Additionally 15 full-length reference sequences of HBV/D4 used in this study and indicated in supplementary table 1 have the GenBank accession numbers:
FJ692532,FJ692533,FJ692536,AJ627219,AB048701,AB048702,AB048703,AB033559,HE974372,HE974373,HE974378,HE974382,GQ922003,GQ922004,GQ922005.
Funding: This work was supported by the Indian Council of Medical Research, NER/2/2008-ECD-I [B]. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: seemdatt@gmail.com
Introduction
The striking genetic heterogeneity displayed by HBV result
mostly from copy errors introduced by viral polymerase during
replication of its DNA genome through reverse transcription of
pregenomic RNA [1]. However, the long-term fate of these
abundant genetic changes depend upon the interactions of HBV
with its host, the dramatic intra-host diversification and on
different genetic processes such as selection, recombination,
genetic drift, population dynamics, and biogeography [1].
Comparisons of HBV sequences from different geographical
regions revealed the presence of ten genotypes (A–J), defined by
genome dissimilarity by more than 7.5% and most genotypes
further segregate into subgenotypes that differ from each other by
4–7.5% [1]. Among them, Genotype D (HBV/D) is most
widespread and comprised of 9 subgenotypes (D1–D9), of which
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109425
D1–D3 appear worldwide while D4–D9 have a more restricted
distribution [1,2].
HBV infection is extremely common in India that is remarkable
for its rich population genomic diversity [3]. Taking into
consideration the parallelism between HBV-host co-evolution,
the diverse Indian population provides an excellent opportunity to
study the underpinnings of HBV diversity and disease biology. Of
the three genotypes of HBV, D, A and C found in India, HBV/D
is predominant and five D-subgenotypes, D1, D2, D3, D5 and D9
had been reported with different local distributions [1,3].
However, there is very limited information on molecular
epidemiology of HBV from North-East (N-E) India that has
always been a hotspot for population geneticists due to the
presence of linguistically, culturally and demographically varied
population. Owing to its strategic geographic location, being
hemmed in by countries like China, Myanmar, Bhutan and
Bangladesh on three sides, the N-E region serve as a gateway
connecting India to East/South-East Asia and had been a corridor
of extensive human migration in the past. Moreover, studies on N-
E Indian populations indicated that their mitochondrial DNA and
Y-chromosome gene pools show closer genetic affinities with East/
South-East Asian groups than with mainland Indian population
[4].
Seven contiguous States (Arunachal Pradesh, Assam, Manipur,
Meghalaya, Mizoram, Nagaland and Tripura) make up the N-E
part of the country of which Tripura is the smallest state with a
population of about 36.71 lakhs (2011 census). It had a
predominantly tribal population in the past but the huge wave
of immigration from neighboring Bangladesh in post-indepen-
dence era had resulted in its demographic transformation
rendering its indigenous tribal population to a minority [5].
Hepatitis B positivity has been found to be about 4% in Tripura
[6]. We initiated the present study to assess the distribution of viral
genotypes/subgenotypes in chronically HBV infected patients of
Tripura and in the process report for the first time the presence of
subgenotype D4 in India and the emergence unique molecular
signatures in these isolates that distinguished them from previously
reported D4 strains and results in their separate clustering as a new
clade that we designate as Indian D4 (IndD4).
Materials and Methods
Collection of blood samples
Five millilitre blood was collected with informed written consent
from seventy six treatment-naı¨ve chronically HBV infected
patients reporting at Agartala Government Medical College,
Agartala, Tripura, between 2010 to 2012. Patients with other viral
infections and history of significant alcohol intake were excluded.
The serum was separated and stored at 280uC until use. The
study was approved by Ethical Review Committee of Agartala
Government Medical College, Agartala, Tripura.
Testing of serological markers and liver enzymes
Each serum sample was tested for the levels of liver enzymes
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) using commercially available kits from Bayer Diagnostics
(India) in a semiautomated biochemistry analyzer (RA-50; Bayer).
The normal ranges for AST and ALT are 2 to 45 IU/liter and 2 to
40 IU/liter, respectively. Serological markers for hepatitis B virus
surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg)
and antibodies to HBeAg (anti-HBeAg) were also checked in each
sample, using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits from General Biologicals, Taiwan, and
bioMe’rieux, Boxtel, Netherlands.
HBV DNA isolation and quantification
HBV DNA was extracted from 200 ml sera using QIAamp
DNA Mini kit (Qiagen Inc., Valencia, CA). Viral DNA titer was
Table 1. Primers used in this study.





F7 59 -TGTGCACTTCGCTTCACCTC -39 1578–1597
F8 59 -ATTTGCATACTCTTTGGAAGGC-39 2746–2767





R8 5’-CTTTGACAAACTTTCCAATCAAT- 3’ 973–995




P1y 5’ -CCGGAAAGCTTGAGCTCTTCTTTTTCACCTCTGCCTAATCA- 39 1821–1841
P2y 5’-CGGAAAGCTTGAGCTCTTCAAAAAGTTGCATGGTGCTGG- 39 1823–1806
** = nucleotide [nt] positions are given according to HBV sequence with accession no. AF121242 obtained from GenBank.
yGunther S et al. J. Virol. 1995; 69: 5437–44.
doi:10.1371/journal.pone.0109425.t001
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determined by real time PCR using Roche Diagnostics Cobas
Taqman 48 (Roche Diagnostics Molecular Systems, Alameda,
CA) and the lower limit of detection was 20 IU/ml.
Amplification and sequencing of HBV genome
The preS1/preS2/S region of HBV was amplified from each
sample by PCR using primers F8 and R9 (Table 1) while for
samples with low viral load, a second round of amplification with
nested primer pair F3 and R8 was performed. Similarly,
amplification of basal core promoter (BCP) and Precore (PC)
region of HBV was carried out with primer pairs F7-R2 and F1-
SP2 (Table 1) in single or two-step nested PCR reactions as
appropriate. From selected samples full length HBV DNA was
amplified with primers P1 and P2 (Table 1). In case of low HBV
DNA level, a second round nested PCR was subsequently
performed using two different primer sets, MP1 with R5 and F3
with MP2 [1]. All PCR products were purified by the QIA quick
Gel Extraction Kit (Qiagen, CA) and the nucleotide sequences
were determined using BigDye terminator cycle sequencing kit
(AB Applied Biosystems, Foster City, CA) on automated DNA
sequencer (ABI Prism 3130). DNA sequence editing and analysis
were performed using Seqscape V2.5 (Applied Biosystems)
software.
Phylogenetic analyses of HBV sequences and estimation
of divergence time
To determine HBV genotype/subgenotype, preS/S as well as
full-length HBV sequences obtained in the study were compared
with representative sequences of 10 genotypes (A–J) as well as that
of subgenotypes of A (A1–A7), C (C1–C16) and D (D1–D9)
retrieved from GenBank. Sequence alignments were carried out
using CLUSTAL_X software and phylogenetic trees were
constructed by neighbour-joining method using Kimura 2
parameter model in MEGA software version-5 (www.
megasoftware.net). To confirm the reliability of phylogenetic tree
analysis, bootstrap resampling and reconstruction were carried out
5000 times. Sequence variability was analyzed with the help of
multiple alignment data. The evolutionary relationship between
the non-recombinant D-subgenotypes (D1 to D7) was examined
using a likelihood method of the DNAMLK program of PHYLIP
package (http://evolution.genetics.washington. edu/phylip.html),
which uses a ‘molecular clock’ assumption.
Investigation of Recombination events
To detect recombination events in HBV genome sequences, a
circular version of jumping profile hidden Markov model
(jpHMM) available online at http://jphmm.gobics.de/
submission_hbv.htm was used as described previously [1].
Statistical analysis
The data were analyzed in GraphPad PRISM v5 software. The
results were presented as median (range) or mean6 standard
deviation (SD) as applicable. For comparison of quantitative
variable, one-way ANOVA or the Mann-Whitney tests were used
and for all tests performed, a p-value ,0.05 was considered as
significant.
Figure 1. Phylogenetic tree of 12 Indian HBV strains belonging
to subgenotype D4. The tree was formed on the basis of full-length
HBV sequences. The reference sequences of different D-subgenotypes
(D1-D9) retrieved from GenBank are indicated by their accession
numbers. Indian HBV/D4 sequences of this present study are indicated
by the respective isolate number beginning with ‘‘TP’’.
doi:10.1371/journal.pone.0109425.g001
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Nucleotide sequence accession numbers
The complete nucleotide sequences of 12 IndD4 isolates are
available in DDBJ/EMBL/GenBank databases under accession
numbers KF192830 -KF192841.
Results
Distribution of HBV genotypes and subgenotypes in
Tripura
The phylogenetic analysis of 76 PreS/S sequences of HBV from
chronic carriers of Tripura revealed the presence of three distinct
genotypes; D, C and A. Sixty eight HBV isolates (89.5%) belonged
to genotype D, 5 (6.6%) were of genotype C and 3 (3.9%) clustered
with genotype A (figure not shown). While all the HBV/A and
HBV/C isolates belonged to subgenotype A1 and C1 respectively,
genotype D strains were found to be most divergent and
segregated into 5 distinct subsegenotypes. Thirty six of 68 HBV/
D (52.94%) were found to cluster with subgenotype D3, 14 isolates
(20.59%) were grouped in D2, 4 (5.88%) belonged to D1 and one
(1.47%) to D5. Notably, the remaining 13 HBV/D sequences
(19.1%) formed a separate clade within subgenotype D4 (Figure
S1). HBV/D4 was not previously reported from any part of India
and for a more detailed analysis of these strains, complete genome
amplification and sequencing was successfully done in 12 D4-
isolates. The phylogenetic tree constructed on basis of these full-
length sequences once again placed the IndD4 strains in a separate
clade within D4-subgenotype cluster, the branching being
supported by high bootstrap value (Figure 1). The estimated
intergroup nucleotide divergence (mean 6 SD) between IndD4
and other global D4 sequences was found to be 2.7% while it was
between 4% –5.2% with respect to other D-subgenotypes
(Table 2). Moreover, none of the 12 HBV/D4 showed any
evidence of recombination in their genome as determined by
jpHMM method (data not shown). We examined the evolutionary
relationships between IndD4 and other non-recombinant D-
subgenotypes (D1–D7) and in our likelihood estimation of the tree
(Figure 2), almost all representative strains were grouped accord-
ing to their subgenotypes. The only exception was the sequence
V01460, which was placed outside the D3 group and used as an
outgroup to root the tree. The branching event showed that
IndD4 was significantly distant and evolutionary more recent than
D4 from other parts of the globe.
Signature residues of HBV/IndD4 in different ORFs and
regulatory regions
Prior to this study, a total of 15 full-length sequences of HBV/
D4 were available in GenBank (Table S1). We compared the
deduced amino acid sequences of all four overlapping open
reading frames (ORFs), namely pre-S1/pre-S2/S, X, pre-C/C
and P in all 12 IndD4 isolates with the existing D4 sequences as
well as with other D-subgenotypes (D1–D9) to identify signature
motifs of IndD4. IndD4 differed from the global HBV/D4 by 19
amino acid residues of which 12 residues were found in P ORF,
one each in PreS1, PreS2 and PreC/C region and two each in S
and X ORFs (Table 3).Of these 19 residues, 10 residues namely
T120 in S region, L11 in X ORF, N87and E90 in the terminal
protein (tp) region, F30 and A62 in spacer region (sp), N128, L267
and Q333 in reverse transcriptase (rt) domain and F50 in
ribonuclease H (rh) region of ORF P are unique to IndD4, i.e.,
are not shared or exhibited by the other D-subgenotypes (Table 3)
and can be considered as molecular signatures of IndD4.
It is noteworthy that T120 and R129 in S region, found in all
IndD4 isolates (Table 3), are two reported HBV mutations with
the potential to escape neutralization by vaccine induced antibody
[7,8] while N128 in rt domain of ORF P has been implicated as a
compensatory or secondary mutation which could increase the
viral fitness of HBV when exits in association with primary drug
resistance mutation against Lamivudine [9].
The expression of HBV genes is controlled by four different
promoters, two enhancers [EnhI [nt. 1074–1234] and EnhII [nt.
1636–1741], a negative regulatory element [NRE; nt. 1613–1636]
and posttranscriptional regulatory elements [PRE] [,nt 1151-
1684]. Novel nucleotide polymorphisms have been perceived in all
IndD4 isolates, two (A3021G and C3033T) in PreS2 promoter,
one (A1126C) in EnhI and three (1310T, 1405T and 1407A) in
PRE that were not seen in any of the D-subgenotypes (D1-D9)
(Table 4).
Biochemical and virological characteristics of infection
with IndD4 in comparison with other D-subgenotypes
We compared the clinical and virological characteristics of
subjects infected with HBV subgenotypes D1-IndD4, while
excluding the single patient carrying D5. A predominance of
chronic HBeAg-negative infection was noted in Tripura where all
subjects harboring IndD4 or D3 and 75% with D1 were negative
for HBeAg (Table 5). Majority of patients with IndD4 had ALT ,
40 IU/L, similar to those with HBV/D2, while AST level as well
as HBV viral load was significantly low in IndD4 as compared to
other 3 subgenotypes (D1–D3) (p,0.05) (Table 5). Mutations in
BCP and PC region of HBV that can decrease or prevent the
synthesis of HBeAg were analyzed in different D-subgenotypes of
HBeAg-negative patients. The double mutation (A1762T and
G1764A) in BCP was undetected in IndD4 although it was found
at a frequency of 33.33% in D1, 8.33% in D2 and 9.09% in D3
isolates. The stop-codon mutation G1896A in PC was noted in
8.33% of each of IndD4 and D2 and in 9.09% of HBV/D3 while
it was absent in D1.
Discussion
In the present study we investigated the prevalence of HBV
genotypes/subgenotypes among chronically HBV infected patients
in the N-E Indian state of Tripura that is geographically remote
from the heartland of India but has rich ethnic diversity and
cultural heritage. HBV/D was predominant in Tripura, similar to
that observed in most parts of India [3], although genotypes C and
A were also detected, albeit at much lower frequencies. However,
few prior studies from other N-E states indicated that HBV/A was
the major genotype in Arunachal Pradesh followed by genotypes
C and D [10]; HBV/D was most common in Assam followed by
genotypes A and C [11] while in Manipur, the occult HBV from
HIV-positive injection drug users belonged mostly to genotype C
[12], thereby reflecting a distinct distribution of viral genotypes in
different N-E states.
Phylogenetic analysis of HBV/D isolates of Tripura revealed
the presence of five D-subgenotypes (D1-D5), the most striking
Figure 2. Estimation of divergence times of non-recombinant HBV subgenotypes D1–D7 including Indian HBV/D4 (IndD4). The tree
was constructed by the DNAMLK program of the PHYLIP package, using indel-free HBV sequences of different subgenotypes of D, derived from
GenBank, along with 12 IndD4 sequences. Reference sequences are indicated by their specific subgenotypes followed by accession numbers and the
IndD4 sequences are indicated by respective isolate numbers beginning with ‘‘TP.’’
doi:10.1371/journal.pone.0109425.g002
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aspect being the detection of subgenotype D4 that is rare in the
world and till date had not been reported from any part of India.
Globally, HBV/D4 has been found in the African nation of
Rwanda [13] and sporadically in Somalia [13], Kenya [14],
Ghana [15] and Morocco [16]. It is also found in the Caribbean
islands of Haiti [13] and Martinique [17] where its spread was
believed to be linked to slave transport from Africa to Caribbean.
This subgenotype has also been encountered in ethnic Microne-
sian community of the Solomon Islands [18], in Aborigines from
Australia, in a blood donor from Papua, New Guinea [18,19] as
well as in Arctic-native Dene population of Canada [20]. HBV/
D4 has been reported from the Brazilian state of Rondoˆnia whose
inhabitants are mainly descendants from European colonizers,
African slaves, and Native Americans [21]. In this study we
observed that ,19% of HBV/D sequences from Tripura
belonged to D4. Both partial and complete genome analyses
showed that these strains formed a distinct clade within D4, with a
high bootstrap value, segregating from both African and
Australian D4 isolates.
Molecular epidemiology of HBV suggests that it followed
modern human since their dispersal from Africa and the genesis of
global genetic tapestry of HBV and the emergence of different
genotype/subgenotype resulted from multiple founder events that
occurred during their long march with their host across the
continents [22]. Given that a sizeable percentage of HBV/D4 was
found in individuals of African origin, it is tempting to speculate
that D4 might have originated in Africa and had followed the early
wave of human migration via a southern route around the coasts
of Indian Ocean to South-East Asia and ultimately to Melanesia
and Australia [23,24]. The spread of D4 among the Native
Americans (including Na-Den’e Indians) might be linked with later
migratory events that occurred subsequent to the colonization of
East Asia and the northward diffusion of Asian migrants as far as
Siberia and their arrival into American continent from the
Beringian landmass [25]. The introduction of HBV/D4 in India
might be more recent and given its sole presence in N-E India, it
could be envisaged that its advent might have been associated with
the settlement of proto-Tibeto-Burman people, who are exclusive
to this region and had migrated from East Asia [26]. Our analysis
of D4 sequences from different geographical regions and
calibrating a molecular clock based on observed nucleotide
changes suggested that IndD4 diverged more recently than
African and Australian isolates, giving credence to our hypothesis
of their relatively recent arrival to India. The narrow strip of land
that connects the N-E Indian region to the remaining part of India
has served has a bottleneck to the dispersal of Tibeto-Burman
immigrants who thus remained land-locked in this region and
concurrently HBV/D4 might have been circulating and evolving
in isolation in this region for many years unnoticed. Tripura is
home to a plethora of ethnic groups, most of whom derived their
ancestry from Tibeto-Burman family and future studies of HBV
genotype/subgenotype in these primitive communities can shed
more light into the genetic geography of the virus as well as the as
the history and demography of its host and viral transmission
between communities.
The multiple episodes of human migration had also been
associated with their significant genetic differentiation and by
extrapolation, seem to have influenced the evolutionary trajectory
of HBV that is reflected in the emergence of unique signature
residues across its four ORFs and regulatory regions. By
comparing the amino acids of IndD4 with the available global
D4 as well as with other D-subgenotypes, we were able to identify
10 signature residues that were exclusive to IndD4. The most
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present within the major hydrophilic region (aa 99-169) of S ORF.
It has been reported that T120 and R129 can cause reduced binding
affinity to anti-HBs or vaccine-induced antibodies [7,8], which
may contribute to the establishment of persistent infection in both
unvaccinated and vaccinated individuals. Moreover, both these
residues, particularly R129, significantly reduced the extracellular
level of S proteins and also impair the secretion of subviral
particles and virions in vitro and in vivo [27]. This may result in
HBsAg detection failure, misdiagnosis of hepatitis B among HBV/
D4 cases and transmission of HBV from ‘occult’ infected blood
donors. Moreover it also provides a plausible explanation to the
low viral titers observed in individuals with IndD4. Reduced virion
secretion may also cause the intrahepatic retention of virions and S
proteins, which can induce endoplasmic reticulum stress and
promote inflammation [28] and thus a long term carriage of
IndD4 may lead to more severe liver disease. The presence of T120
in S ORF also creates the rtT128N exchange in overlapping P
ORF. It has been reported that rtN128 substitution can restore the
replication fitness of lamivudine-resistant HBV mutants carrying
changes in YMDD motif in presence of the drug [9], thereby
limiting the long-term efficacy of nucleoside analogue therapy for
IndD4-bearing patients and supporting the need of their close
surveillance and treatment adjustments. All IndD4 also harbored
novel nucleotide substitutions in PreS2 promoter, EnhI and PRE
but their implications on HBV transcription and replication and
their impact on viral pathogenicity warrants further investigation.
Since the patients with IndD4 maintained a significantly low
viral load as compared to those with other D-subgenotypes, it
appears that IndD4 may have an inherently low replicative
capacity. While a rapidly replicating virus through generation of a
larger antigen pool could be easily recognized by host immune
system, a lowly replicating virus, such as IndD4, would evoke a
weaker immune response and thereby have an increased chance of
persistence that in turn may result in progressive liver disease.
The absolute predominance of HBeAg-negative infection and
the near complete absence of BCP/PC mutations characterize the
IndD4 infected patients. It has been shown that the genetic
diversity of HBV is highest during periods of high viral replication
and a mounting immune response, while the mutation rate
appears to be low, when the host immune response is relatively
quiescent [29]. Most IndD4 carrying HBeAg-negative subjects in
the present study had biochemically inactive infection and it is
possible that the relatively quiescent and inactive virological status
and stable immunological status negatively influenced the emer-
gence and evolution of PC/BCP mutants as the predominant
species over the wild-type sequences.
Taken together, the relative isolation of Tripura and its ethnic
constitution served as a protection against the spread of HBV/
IndD4 and may explain its absence in other parts of the country.
The study also reiterates the fact the HBV can serve as an ideal
surrogate marker to study human population movements and
ancestry and can help to unravel many strongly debated topics in
human history. Although IndD4 may appear rather innocuous to
its carriers owing to low viral load and normal levels of ALT/AST
but the presence of unique genetic signatures that favor immune/
vaccine escape, drug resistance and long-term persistence in host
can make it an emerging clinical challenge with the potential of
undermining the success of vaccination programs or anti-viral
therapy.
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Figure S1 Phylogenetic tree showing the subgenotypic
distribution of 68 HBV strains belonging to genotype D
from Tripura. The tree was formed on the basis of PreS/S
sequences. The reference sequences of different subgenotypes of
D, namely, D1 to D9, retrieved from GenBank are indicated by
their accession numbers while HBV/D sequences determined in
the present study are indicated by their respective isolate numbers
beginning with ‘‘TP’’.
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